Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-26-300874
Filing Date
2026-07-10
Accepted
2026-07-10 16:05:14
Documents
16
Period of Report
2026-08-14

Document Format Files

Seq Description Document Type Size
1 DEF 14A ck0001774857-20260710.htm   iXBRL DEF 14A 891170
2 GRAPHIC img37144761_0.jpg GRAPHIC 25798
3 GRAPHIC img37144761_1.jpg GRAPHIC 77543
4 GRAPHIC img37144761_2.jpg GRAPHIC 77543
5 GRAPHIC img37144761_3.jpg GRAPHIC 2834312
6 GRAPHIC img37144761_4.jpg GRAPHIC 2032143
  Complete submission text file 0001193125-26-300874.txt   12554769

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ck0001774857-20260710.xsd EX-101.SCH 7487
21 EXTRACTED XBRL INSTANCE DOCUMENT ck0001774857-20260710_htm.xml XML 6490
Mailing Address 4370 LA JOLLA VILLAGE DRIVE SUITE 1050 SAN DIEGO CA 92122
Business Address 4370 LA JOLLA VILLAGE DRIVE SUITE 1050 SAN DIEGO CA 92122 (858) 225-7696
Aardvark Therapeutics, Inc. (Filer) CIK: 0001774857 (see all company filings)

EIN.: 821606367 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-42513 | Film No.: 261168773
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)